PMDAsafety guidance72% confidence
[SHINSA]Four English-language Early Considerations have been published, including those on biosimilars, in vivo diagnostics, and vaccines.
Source: PMDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Oncology · Liver Cancer
- Sub-indication
- Liver Cancer
Related signal: Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
Source
FDA document
View source